Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Myeloid, Chronic-Phase 3Polycythemia Vera 2Neoplasm Metastasis 2Carcinoma, Renal Cell 2Uveal Melanoma 1Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Recurrence 1Primary Myelofibrosis 1Osteosarcoma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurofibroma 1Neoplasms 1Metastatic Gastrointestinal Carcinoid Tumor 1Lymphoma, Non-Hodgkin 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia 1Kidney Neoplasms 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Graft vs Host Disease 1Glioma 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1

Interventions

tipifarnib 1peginterferon alfa-2b 1nilotinib 1mirdametinib 1binimetinib 1Vincristine 1Temozolomide 1Sirolimus 1Ranibizumab 1Radiosurgery 1Mn-PyC3A 1Imatinib Mesylate 1Everolimus 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neurofibroma × peginterferon alfa-2b × Clear all
NCT00846430 2023-08-30

Medical Treatment of "High-Risk" Neurofibromas

Corewell Health West

Phase 2 Completed
9 enrolled 9 charts
CNS

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡